Phase 3 Head and Neck Cancer Trial, Recruiting NCT05044117 Sponsor: Sun Yat-sen University Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT05044117
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are generally healthy and able to carry out daily activities with little or no limitation (your doctor may refer to this as ECOG performance status 0 or 1).
  • You have been newly diagnosed with a confirmed squamous cell cancer (a specific type of cancer) of the mouth, throat, voice box, or lower throat area, and it has been classified as an advanced stage (Stage III or IV).
  • You have completed one of the following treatments: surgery followed by radiation or combined radiation and chemotherapy; pre-treatment therapy followed by radiation or combined radiation and chemotherapy; or combined radiation and chemotherapy alone.
  • If you had surgery, your radiation treatment started between 4 and 8 weeks after your surgery was completed.
  • You are enrolling between 4 and 8 weeks after your last radiation treatment was finished.
  • There is no sign that your cancer is still active in the treated area or has spread to other parts of your body before joining the trial.
  • Your blood counts, liver function, and kidney function are all within acceptable levels (your doctor will check this with blood tests).
  • You are willing to be informed about the research nature of the study and sign a consent form agreeing to take part.

Who may not be able to join:

  • Your cancer tests positive for a protein called p16 (confirm with trial site).
  • You are known to be unable to tolerate or are allergic to a drug called capecitabine.
  • You have a condition that makes it difficult to take medication by mouth, such as trouble swallowing, ongoing severe diarrhea, or a bowel blockage.
  • You have had a previous cancer, unless it was an early-stage skin cancer or a non-spreading cervical condition that has already been successfully treated.
  • You are currently pregnant or breastfeeding (women who could become pregnant will be asked to take a pregnancy test and to use effective contraception during the trial).
  • You received surgery, chemotherapy, radiation, or other cancer treatments to the affected area before your main course of treatment (diagnostic procedures do not count).
  • You received surgery, biological therapy, or immunotherapy at the same time as your radiation treatment.
  • You are currently receiving, or are very likely to receive, other chemotherapy, biological therapy, or immunotherapy after your radiation treatment has finished.
  • You have another serious ongoing health condition that could put you at unacceptable risk or make it hard to follow the trial requirements — for example, unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, or significant emotional or mental health difficulties.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ying Sun, M.D., Sun Yat-sen University

Phone: +86-(020)-87343816

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
18 October 2021
Est. completion
1 October 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov